214 related articles for article (PubMed ID: 33816781)
1.
Sakemura R; Can I; Siegler EL; Kenderian SS
Mol Ther Oncolytics; 2021 Mar; 20():625-633. PubMed ID: 33816781
[TBL] [Abstract][Full Text] [Related]
2. Development of a Clinically Relevant Reporter for Chimeric Antigen Receptor T-cell Expansion, Trafficking, and Toxicity.
Sakemura R; Bansal A; Siegler EL; Hefazi M; Yang N; Khadka RH; Newsom AN; Hansen MJ; Cox MJ; Manriquez Roman C; Schick KJ; Can I; Tapper EE; Nevala WK; Adada MM; Bezerra ED; Kankeu Fonkoua LA; Horvei P; Ruff MW; Parikh SA; Pandey MK; DeGrado TR; Suksanpaisan L; Kay NE; Peng KW; Russell SJ; Kenderian SS
Cancer Immunol Res; 2021 Sep; 9(9):1035-1046. PubMed ID: 34244299
[TBL] [Abstract][Full Text] [Related]
3. Optimizing Manufacturing Protocols of Chimeric Antigen Receptor T Cells for Improved Anticancer Immunotherapy.
Stock S; Schmitt M; Sellner L
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31835562
[TBL] [Abstract][Full Text] [Related]
4. Anti-CD123 chimeric antigen receptor T-cells (CART): an evolving treatment strategy for hematological malignancies, and a potential ace-in-the-hole against antigen-negative relapse.
Cummins KD; Gill S
Leuk Lymphoma; 2018 Jul; 59(7):1539-1553. PubMed ID: 28901790
[TBL] [Abstract][Full Text] [Related]
5. Influence of Retronectin-Mediated T-Cell Activation on Expansion and Phenotype of CD19-Specific Chimeric Antigen Receptor T Cells.
Stock S; Hoffmann JM; Schubert ML; Wang L; Wang S; Gong W; Neuber B; Gern U; Schmitt A; Müller-Tidow C; Dreger P; Schmitt M; Sellner L
Hum Gene Ther; 2018 Oct; 29(10):1167-1182. PubMed ID: 30024314
[TBL] [Abstract][Full Text] [Related]
6. Quantitative Systems Pharmacology Model of Chimeric Antigen Receptor T-Cell Therapy.
Hardiansyah D; Ng CM
Clin Transl Sci; 2019 Jul; 12(4):343-349. PubMed ID: 30990958
[TBL] [Abstract][Full Text] [Related]
7. Idelalisib for optimized CD19-specific chimeric antigen receptor T cells in chronic lymphocytic leukemia patients.
Stock S; Übelhart R; Schubert ML; Fan F; He B; Hoffmann JM; Wang L; Wang S; Gong W; Neuber B; Hückelhoven-Krauss A; Gern U; Christ C; Hexel M; Schmitt A; Schmidt P; Krauss J; Jäger D; Müller-Tidow C; Dreger P; Schmitt M; Sellner L
Int J Cancer; 2019 Sep; 145(5):1312-1324. PubMed ID: 30737788
[TBL] [Abstract][Full Text] [Related]
8. Multiparameter comparative analysis reveals differential impacts of various cytokines on CART cell phenotype and function ex vivo and in vivo.
Xu XJ; Song DG; Poussin M; Ye Q; Sharma P; Rodríguez-García A; Tang YM; Powell DJ
Oncotarget; 2016 Dec; 7(50):82354-82368. PubMed ID: 27409425
[TBL] [Abstract][Full Text] [Related]
9. CART Cell Toxicities: New Insight into Mechanisms and Management.
Zahid A; Siegler EL; Kenderian SS
Clin Hematol Int; 2020 Dec; 2(4):149-155. PubMed ID: 33409484
[TBL] [Abstract][Full Text] [Related]
10. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma.
Cohen AD; Garfall AL; Stadtmauer EA; Melenhorst JJ; Lacey SF; Lancaster E; Vogl DT; Weiss BM; Dengel K; Nelson A; Plesa G; Chen F; Davis MM; Hwang WT; Young RM; Brogdon JL; Isaacs R; Pruteanu-Malinici I; Siegel DL; Levine BL; June CH; Milone MC
J Clin Invest; 2019 Mar; 129(6):2210-2221. PubMed ID: 30896447
[TBL] [Abstract][Full Text] [Related]
11. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma.
O'Rourke DM; Nasrallah MP; Desai A; Melenhorst JJ; Mansfield K; Morrissette JJD; Martinez-Lage M; Brem S; Maloney E; Shen A; Isaacs R; Mohan S; Plesa G; Lacey SF; Navenot JM; Zheng Z; Levine BL; Okada H; June CH; Brogdon JL; Maus MV
Sci Transl Med; 2017 Jul; 9(399):. PubMed ID: 28724573
[TBL] [Abstract][Full Text] [Related]
12. Bridging Radiation Therapy Before Commercial Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Aggressive B-Cell Lymphoma.
Wright CM; LaRiviere MJ; Baron JA; Uche C; Xiao Y; Arscott WT; Anstadt EJ; Barsky AR; Miller D; LaRose MI; Landsburg DJ; Svoboda J; Nasta SD; Gerson JN; Barta SK; Chong EA; Schuster SJ; Paydar I; Maity A; Plastaras JP
Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):178-188. PubMed ID: 32446950
[TBL] [Abstract][Full Text] [Related]
13. Phase I Study of Chimeric Antigen Receptor-Modified T Cells in Patients with EGFR-Positive Advanced Biliary Tract Cancers.
Guo Y; Feng K; Liu Y; Wu Z; Dai H; Yang Q; Wang Y; Jia H; Han W
Clin Cancer Res; 2018 Mar; 24(6):1277-1286. PubMed ID: 29138340
[No Abstract] [Full Text] [Related]
14. Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus-Driven Production of a Bispecific T-cell Engager.
Wing A; Fajardo CA; Posey AD; Shaw C; Da T; Young RM; Alemany R; June CH; Guedan S
Cancer Immunol Res; 2018 May; 6(5):605-616. PubMed ID: 29588319
[TBL] [Abstract][Full Text] [Related]
15. The clinical study on treatment of CD19-directed chimeric antigen receptor-modified T cells in a case of refractory Richter syndrome.
Xia L; Wang Y; Li T; Hu X; Chen Q; Liu L; Jiang B; Li C; Wang H; Wang S; Yang G; Bao Y
Cancer Med; 2019 Jun; 8(6):2930-2941. PubMed ID: 31050207
[TBL] [Abstract][Full Text] [Related]
16. Chimeric antigen receptor T cells targeting CD147 for non-small cell lung cancer therapy.
Chen XH; Chen R; Shi MY; Tian RF; Zhang H; Xin ZQ; Chen ZN; Wang K
Transl Oncol; 2022 Feb; 16():101309. PubMed ID: 34896852
[TBL] [Abstract][Full Text] [Related]
17. Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma.
Feng KC; Guo YL; Liu Y; Dai HR; Wang Y; Lv HY; Huang JH; Yang QM; Han WD
J Hematol Oncol; 2017 Jan; 10(1):4. PubMed ID: 28057014
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers.
Feng K; Liu Y; Guo Y; Qiu J; Wu Z; Dai H; Yang Q; Wang Y; Han W
Protein Cell; 2018 Oct; 9(10):838-847. PubMed ID: 28710747
[TBL] [Abstract][Full Text] [Related]
19. Chimeric antigen receptor T-cell therapy: Challenges and framework of outpatient administration.
Gatwood KS; Dholaria BR; Lucena M; Baer B; Savani BN; Oluwole OO
EJHaem; 2022 Jan; 3(Suppl 1):54-60. PubMed ID: 35844300
[TBL] [Abstract][Full Text] [Related]
20. What is the Role of Hematopoietic Cell Transplantation (HCT) for Pediatric Acute Lymphoblastic Leukemia (ALL) in the Age of Chimeric Antigen Receptor T-Cell (CART) Therapy?
Taraseviciute A; Broglie L; Phelan R; Bhatt NS; Becktell K; Burke MJ
J Pediatr Hematol Oncol; 2019 Jul; 41(5):337-344. PubMed ID: 30973486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
